Damned If You Do and Damned If You Don’t

“These patients say they cannot afford to wait for research results because they will wind up in wheelchairs before the studies are done. Read more

Venous Anatomy in CCSVI a condition that may potentially contribute to the symptoms of MS

Review of Venous Anatomy for Venographic Interpretation in Chronic Cerebrospinal Venous InsufficiencyRead more

How Safe is The Endovascular Treatment for CCSVI?

Safety of Endovascular Treatment of Chronic Cerebrospinal Venous Insufficiency: A Report of 240 Patients with Multiple SclerosisRead more

Venous Angioplasty. Is it Safe and Have Any Benefits For MS Patients?

Comments regarding ‘Venous Angioplasty is Safe to Perform and May Have Benefits Forin Patients with Multiple Sclerosis. Results of a Pilotcase Control Pilot Study’Read more

CCSVI and MS: A Never-Ending Story

The first paper on this topic was published in 2006 by Dr Zamboni, an Italian vascular surgeon, and was titled: ‘The big idea: iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis’.1 It was not picked up, probably because it was published in a dubious e-journal with the prestigious name: ‘The Royal Society of Medicine’.Read more

The mesenchymal stem cells in multiple sclerosis

Background: No treatments are currently available that slow, stop, or reverse disease progression in established multiple sclerosis (MS). The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) trial tests the safety and feasibility of treatment with a candidate cell-based therapy, and will inform the wider challenge of designing early phase clinical trials to evaluate putative neuroprotective therapies in progressive MS. Illustrated by the MSCIMS trial protocol, we describe a novel methodology based on detailed assessment of the anterior visual pathway as a model of wider disease processes - the “sentinel lesion approach”. Read more